Cold activation of complement for monitoring the response to interferon in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 91, Issue 2, 1996, Pages 319-327

  Akahane, Yoshihiro ^b   Miyazaki, Yoshiki ^b   Naitoh, Shigeko ^b   Takeda, Kiyoshi ^b   Tsuda, Fumio ^b   Okamoto, Hiroaki ^b   Itoh, Keiichi ^b   Miyakawa, Yuzo ^b   Mayumi, Makoto ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; INTERFERON;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHRONIC HEPATITIS; COMPLEMENT ACTIVATION; DRUG MONITORING; FEMALE; HEMOLYSIS; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIREMIA; VIRUS INFECTION;

ADULT; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; COLD; COMPLEMENT ACTIVATION; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEMOLYSIS; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, VIRAL; TIME FACTORS;

EID: 0030047754     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Dienstag JL, Bhan AK, Alter HJ, et al. Circulating immune complexes in non-A, non-B hepatitis. Possible masking of viral antigen. Lancet 1979;1:1265-7.
2. Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
3. Hijikata M, Shimizu YK, Kato H, et al. Equilibrium centrifugation studies of hepatitis C virus: Evidence for circulating immune complexes. J Virol 1993;67:1953-8.
4. Ferri C, Greco F, Longombardo G, et al. Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 1991;34: 1606-10.
5. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327:1490-5.
6. Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573-7.
7. Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328:465-70.
8. Kitamura H, Nagaki K, Inoshita K, et al. The cold activation of the classical complement pathway: The cause of the differences between plasma and serum complement in liver cirrhosis. Clin Exp Immunol 1977;27:34-7.
9. Ueda K, Nakajima H, Nakagawa T, et al. The association between hepatitis C virus infection and in vitro activation of the complement system. Ann Clin Biochem 1993;30:565-9.
10. Itoh K, Tanaka H, Shiga J, et al. Hypocomplementemia associated with hepatitis C viremia in sera from voluntary blood donors. Am J Gastroenterol 1994;89:2019-24.
11. de Groote J, Desmet VJ, Gedigk P, et al. A classification of chronic hepatitis. Lancet 1968;2:626-8.
12. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
13. Mishiro S, Hoshi Y, Takeda K, et al. Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: Implication for an autoimmune process. Lancet 1990;336:1400-3.
14. Okamoto H, Okada S, Sugiyama Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60:215-22.
15. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73: 673-9.
16. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol 1993;74:2385-90.
17. Mori S, Kato N, Yagyu A, et al. A new type of hepatitis C virus in patients in Thailand. Biochem Biophys Res Commun 1992;183:334-42.
18. Chan SW, McOmish F, Holmes EC, et al. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. J Gen Virol 1992;73:1131-41.
19. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-9.
20. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
21. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989;321:1501-6.
22. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
23. Chayama K, Saitoh S, Arase Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-3.
24. Shindo M, Di BA, Cheung L, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-4.
25. Hino K, Sainokami S, Shimoda K, et al. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol 1994;42:299-305.
26. Zaaijer HL, Cuypers HT, Reesink HW, et al. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet 1993;341: 22-4.
27. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992;16: 293-9.
28. Tsubota A, Chayama K, Ikeda K, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
29. Linscott WD, Kane JP. The complement system in cryoglobulinaemia. Interaction with immunoglobulins and lipoproteins. Clin Exp Immunol 1975;21:510-9.
30. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330:751-6.
31. Cacoub P, Fabiani FL, Musset L, et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med 1994;96:124-32.
32. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
33. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: Role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291-300.
34. Atkinson JP, Gorman JC, Curd J, et al. Cold dependent activation of complement in systemic lupus erythematosus. A unique cause for a discrepancy between clinical and laboratory parameters. Arthritis Rheum 1981;24:592-601.
35. Mathews KP, Mentyka RA, Chambers SL, et al. Cold-dependent activation of complement: Recognition, assessment, and mechanism. J Clin Immunol 1992;12:362-70.
36. Akagaki Y, Fujiwara Y, Nakanishi I, et al. The difference between serum and plasma complement activity in primary renal disease. Clin Nephrol 1980;14:75-80.
37. Mayer MM. Complement and complement fixation. In: Kabat and Mayer's experimental immunochemistry, 2nd ed. Illinois: Charles C. Thomas, 1961:133-240.